BG9588 IN PROLIFERATIVE LUPUS GLOMERULONEPHRITIS

$0M01FY2002RRNIH

University Of Pittsburgh At Pittsburgh, Pittsburgh PA

Investigators

Linked publications & trials

Paper 39470729 Paper 38816203 Paper 38746210 Paper 38741246 Paper 38443389 Paper 38204926 Paper 38154770 Paper 38051041 Paper 37978826 Paper 37621304 Paper 37452151 Paper 37436712 Paper 37369443 Paper 37226675 Paper 37220873 Paper 36948887 Paper 36933679 Paper 36323878 Paper 36280384 Paper 36210504 Paper 36182623 Paper 35926332 Paper 35562076 Paper 35453142 Paper 35277935 Paper 35019976 Paper 34897700 Paper 34875344 Paper 34789471 Paper 34782936 Paper 34753805 Paper 34637524 Paper 34412057 Paper 34162658 Paper 33707304 Paper 33627633 Paper 33619020 Paper 33484937 Paper 33178459 Paper 33168654 Paper 33019960 Paper 32959149 Paper 32845968 Paper 32641237 Paper 32599096 Paper 32564066 Paper 32546565 Paper 32388179 Paper 32325384 Paper 32134326 Paper 32128240 Paper 32085906 Paper 31898874 Paper 31696832 Paper 31559418 Paper 31451118 Paper 31338998 Paper 31131339 Paper 31112370 Paper 30997482 Paper 30900413 Paper 30898391 Paper 30883031 Paper 30833373 Paper 30499236 Paper 30421851 Paper 30201101 Paper 30054336 Paper 30052546 Paper 29846553 Paper 29555990 Paper 29545462 Paper 29502561 Paper 29204699 Paper 29186515 Paper 29159267 Paper 29086498 Paper 29053861 Paper 29049607 Paper 29029385 Paper 28994902 Paper 28958022 Paper 28940967 Paper 28678345 Paper 28633381 Paper 28344345 Paper 28263092 Paper 28171850 Paper 28152263 Paper 28103614 Paper 28063166 Paper 28035019 Paper 27911851 Paper 27898207 Paper 27698005 Paper 27685338 Paper 27676466 Paper 27595995 Paper 27595918 Paper 27533245

Abstract

This is a Phase II, multicenter, open label study of BG9588 (Biogen's humanized anti-CD40L monoclonal antibody) in subjects with SLE GN. The primary objective is to determine if BG9588 can reduce proteinuria by greater than 50% from baseline at two consecutive visits between Day 57 and Day 141, without worsening of renal function, in subjects with WHO Class III, IV or mixed membranous and proliferative SLE GN. The secondary objectives are to determine the safety and pharmacokinetics of BG9588 and its effects on serum C3 complement levels, hematuria, urinary cellular casts, anti-dsDNA titers, SELENA-SLEDAI and SF36TM.

View original record on NIH RePORTER →